A c c e p t e d m a n u s c r i p t ACCEPTED ARTICLE PREVIEW Abstract Therapeutic angiogenesis is a major goal of regenerative medicine, but no clinically approved small molecule exists that enhances new blood vessel formation. Here we show, using a phenotype-driven high-content imaging screen of an annotated chemical library of 1280 bioactive small molecules, that the retinoid agonist Tazarotene, enhances in vitro angiogenesis, promoting branching morphogenesis, and tubule remodeling. The pro-angiogenic phenotype is mediated by Retinoic Acid Receptor (RAR) but not Retinoic X Receptor (RXR) activation, and is characterized by secretion of the pro-angiogenic factors Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor (VEGFA), Plasminogen Activator, Urokinase (PLAU) and Placental Growth Factor (PGF), and reduced secretion of the antiangiogenic factor Pentraxin-3 (PTX3) from adjacent fibroblasts. In vivo, Tazarotene enhanced the growth of mature and functional microvessels in Matrigel implants and wound healing models, and increased blood flow. Notably, in ear punch wound healing model, Tazarotene promoted tissue repair characterized by rapid ear punch closure with normal-appearing skin containing new hair follicles, and maturing collagen fibers. Our study suggests that Tazarotene, an FDA-approved small molecule, could be potentially exploited for therapeutic applications in neovascularization and wound healing.
Introduction
Angiogenesis, the growth of new vessels from pre-existing ones, plays a critical role in tissue renewal and repair. Insufficient angiogenic response occurs in diseases, such as ischemic heart disease, peripheral arterial disease, Alzheimer's disease, ulcers, and chronic wound healing causing dysfunction of repair and regeneration [1] [2] [3] . Currently no clinically approved small molecule exists that enhances new blood vessel formation. Clinical efforts to develop pro-angiogenic therapies have largely focused on administration of single pro-angiogenic growth factors such as VEGF and FGF using recombinant protein or gene transfer technologies 4, 5 , but these are currently viewed as being only modestly successful 6 , possibly because therapeutically beneficial levels of growth factor are not achieved 7 , or that the cooperative molecular interactions necessary for the establishment of a functional vascular network are not achieved through a single growth factor 8 , or indeed that such complex molecular interactions and therapeutic targets are only partially understood.
Phenotype-driven approaches can overcome this knowledge gap by minimizing assumptions regarding molecular interactions and targets and instead focusing directly on functional aspects of vascular network formation 9 . The unbiased identification of therapeutically active molecules using direct phenotypic screens is now possible using high-content microscopy and image analysis algorithms to generate quantitative phenotypic data 10 . Provided an appropriate in vitro model of in vivo angiogenesis is used, such phenotype-driven screens could identify pro-angiogenic molecules that could be therapeutically translated.
The growth of new functional blood vessel network is determined by the extent of branching and tubulogenesis. The endothelial tube formation assay recapitulates most cellular process involves in the assembly of endothelial cells into a primary plexus (e.g. cell-cell, cell-matrix interaction) and has a high predictive value for angiogenesis-related cellular morphogenesis such as vascular branching and, suggesting that this is an appropriate model for in vivo angiogenesis 11, 12 . We developed a high content imaging approach using the endothelial tube formation assay to screen small molecule libraries with aim A c c e p t e d m a n u s c r i p t of identifying novel therapeutic molecules that enhance new blood vessel growth. Here, we identify and characterize Tazarotene, a small molecule that promotes endothelial tubulogenesis and branching. We also demonstrate that systemic delivery of Tazarotene stimulates functional neovascularization and accelerates wound healing.
Results

High content screen of small molecule library using endothelial tube formation assay
The endothelial tube formation assay is quantifiable, rapid, and reproducible, and measures key features of angiogenesis such as branching and tubulogenesis 13 14 . We miniaturized the assay to a 384-well plate format, and established a Z' factor (a statistical measure of assay robustness) for total tube length of 0.33, which is acceptable for high-throughput cell-based screening ( Supplementary Fig. 1 ). To identify small molecules capable of enhancing endothelial tube formation, we screened a Library Of 1280
Pharmacologically Active Compounds (LOPAC) in a 384-well plate format at a final compound concentration of 10 µM. Primary screening of the LOPAC library included four 384-well plates with a Z' factor of 0.48 ±0. 13 and a hit rate of 1.1% for tube formation enhancers and 6.2% for inhibitors ( Supplementary Fig. 2a, Fig. 1 ). As branching points and total tube length were positively correlated ( Supplementary Fig. 2b ), we used total tube length as the parameter for hit selection, using a B-score threshold >+2.6 and <-4 for identifying enhancers and inhibitors respectively. The screen resulted in an initial active compound list of 79 inhibitors and 15 enhancers (Supplementary Table 1 & 2). One enhancer hit was excluded from the list after visual examination of the well images because of a technical artifact. We re-assayed the 14 enhancers using three independent five-point dose dependence trials (1.25 µM to 20 µM) in 96-well plates using the same image analysis algorithm used in the primary screen. Three compounds increased significantly and consistently the total tube length by more that 15% over the negative control ( Fig. 2a) . To re-confirm the results of the screen, we re-examined three active lead compounds in an independent organotypic assay for angiogenesis, in which fibroblasts were co-A c c e p t e d m a n u s c r i p t cultured with endothelial cells (Fig. 2b) . We found that the dopamine re-uptake inhibitor (GBR-12909) reduced tubulogenesis and branching whereas the P38 kinase inhibitor (SB202190) modestly increased the tubulogenesis and branching. The retinoid agonist Tazarotene showed a robust pro-angiogenic activity reflected by around 60% increase in total tube length and branching points compared to controls, and was therefore followed-up further.
Tazarotene promotes endothelial tube remodeling and branching
Tazarotene is a synthetic third generation retinoid that is approved by the US Food and Drug Administration for the topical treatment of plaque psoriasis and acne vulgaris 15 . We measured the EC 50 of Tazarotene (concentration required to enhance the total tube length by 50%) in the organotypic angiogenesis assay. The EC 50 of Tazarotene (800 nM) in this assay is comparable to the EC 50 of other retinoids in cell-based phenotypic assays 16 , suggesting that enhancement of endothelial tube formation was unlikely to be an off-target effect (Fig. 2c ). We observed a distinctive pattern of the organotypic vascular-like network after treatment of Tazarotene, characterized by highly branched, thinner tubes, minimal cell clustering, and increased filopodia formation in the lateral sides of outgrowing endothelial tubes (Fig. 2d ). The increase in branching triggered by Tazarotene was noted from 3 days following endothelial cell seeding onto fibroblasts (the early phase of network formation) ( Supplementary Fig.   3a ). To evaluate the behavior of the newly forming endothelial tubes following Tazarotene treatment, we traced GFP-expressing HUVECs in co-culture by live cell imaging in the initial phase of network formation. Control endothelial cells initially form clusters with minimal remodeling and branch formation at this stage ( Supplementary Fig. 3b ). In contrast, with Tazarotene treatment, endothelial cells elongated and sprouted, and endothelial tubes remodeled more rapidly than controls, becoming thinner with time ( Supplementary Fig. 3b ). However, Tazarotene did not affect endothelial cell motility in single cell culture or in co-culture measured over 24 hours ( Supplementary Fig. 4 ).
VEGFR2 & VEGFR3 expression is very low or absent in most adult blood vessels, but expression is up-
A c c e p t e d m a n u s c r i p t regulated in angiogenic endothelial cells and in endothelial tip cells 17, 18 . We therefore investigated VEGFR2 & VEGFR3 expression in cultured endothelial cells after Tazarotene treatment, and found that it augmented VEGFR3 but not VEGFR2 expression (Fig 2e) . Taken together, these findings show that
Tazarotene induces sprouting behavior of endothelial cells and tubule remodeling.
Tazarotene promotes angiogenesis via retinoic acid receptor activation
The biologically active form tazarotenic acid is produced by esterase hydrolysis of tazarotene in the skin, and binds to three members of the RAR family of retinoid nuclear receptors, with relatively more selectivity for RARβ and RARγ 19 . We therefore investigated whether the observed pro-angiogenic effect of tazarotene is mediated via retinoic acid signaling. We used a pharmacological rather than a genetic approach here as combinatorial isoform specific siRNA for the many retinoid receptor isoforms is technically challenging. To quantify angiogenesis in the experiment set, we measured multiple parameters depicting the vascular-like network in the organotypic angiogenesis assay after different treatments. We then hierarchically clustered the compounds into distinct angiogenic phenotypes based on four angiogenic parameters: total tube length, branching points, tube thickness and total node area.
All-trans-retinoic-acid (ATRA) exhibited the most similar pro-angiogenic phenotype to Tazarotene, suggesting that effects are via the canonical pathway ( Fig. 3a) . Similar effects were observed using 9cis-retinoic acid, which is an intracellular product of ATRA isomerization, confirming the effects of Tazarotene through activation of RAR (Fig. 3a) . While the selective pan RXR agonist (SR 11237) slightly increased total tube length and branching, endothelial tubes were thicker with greater cell clustering (nodes), unlike the Tazarotene-or ATRA-induced phenotypes (Fig. 3a) . We next examined the effect of isoform selective RAR agonists 20, 21 . We found that selectvie RARβ or RARγ agonists (CD2314 and BMS961 respectively) reproduced the distinct pro-angiogenic phenotype of Tazarotene.
The selective RARα agonist (BMS 753) increased overall tube formation to a lesser extent than RARβ or RARγ  agonists (Fig. 3a) . As a complementary approach, we also examined the effect of RAR and A c c e p t e d m a n u s c r i p t RXR blockade on Tazarotene-induced angiogenesis. The addition of the pan-retinoic acid receptor inverse agonist (BMS493) attenuated the ability of Tazarotene to enhance the angiogenesis. In contrast, the incubation of Tazarotene with an RXR antagonist (UVI3003) 22 did not affect the pro-angiogenic phenotype of Tazarotene (Fig. 3b) . These data clearly indicate that the effect of Tazarotene on the branching tubule remodeling is only mediated through RAR binding. We next investigated the effect of Liarozole, a retinoic acid metabolic blocking agent that inhibits the cytochrome P450 (CYP26A1)dependent catabolism of retinoic acid, thereby increasing intracellular retinoic acid 23 . Liarozole treatment induced the tube formation and increased endothelial branching compared to controls (Fig.   3c ). We next examined the expression of RARRES1, a specific downstream target gene for retinoic signaling activation 24 . Tazarotene induced RARRES1 mRNA expression 6-fold in endothelial cells and 40-fold in fibroblasts ( Fig. 3d ). Taken together these data indicate that the pro-angiogenic effect of Tazarotene is through the canonical retinoic acid-signaling pathway via RAR and not RXR activation.
Tazarotene enhances the pro-angiogenic paracrine effects of fibroblasts
Given the known link between cell growth and angiogenesis, we next evaluated cell proliferation following Tazarotene treatment. When endothelial cells were cultured alone, their cell numbers (as measured by DAPI) were decreased slightly after treatment with Tazarotene doses up to 10 µfgM but the decrease was more pronounced at 20 µM. The level of DNA synthesis (as measured by EdU incorporation) did not change significantly (Fig. 4a ). In the organotypic angiogenesis co-culture experiments, endothelial cells were stained with anti-CD31 antibody and subsequently the total cell number and percentage of EdU-positive cells were quantified in both endothelial cells (CD31 + ) and
fibroblasts (CD31 -). We found that Tazarotene treatment did not affect either endothelial or fibroblast cell numbers significantly, at doses up to 10 µM, but reduced fibroblast cell numbers at 20 µM. We also observed an increase in DNA synthesis of fibroblasts at doses from 1-10 µM (Fig. 4b) . Thus there does A c c e p t e d m a n u s c r i p t not appear to be a significant effect of Tazarotene on endothelial cell number or DNA synthesis when they are co-cultured with fibroblasts.
As retinoic acid can induce vascular growth factors such as VEGF and HGF 25, 26 , we next explored the effect of Tazarotene on the secretion of angiogenesis-related factors profile from fibroblasts. Using a comparative proteome profiler array of 55 different cytokines we found that Tazarotene increased the secretion of the vascular growth factors VEGFA, HGF, PGF and PLAU 27 ) whereas the secretion of PTX3, an inhibitor of angiogenesis 28 was decreased ( Fig. 4c ). We found that Tazarotene up regulated PGF mRNA expression, whereas PTX3 mRNA expression was decreased ( Fig. 4d ). Furthermore, we validated the enhanced secretion of PGF and PTX3 by ELISA ( Fig. 4e) . These data suggest that the proangiogenic effect of Tazarotene is more pronounced in the co-culture angiogenesis model partly because of paracrine effects, which amplify the angiogenic response.
Tazarotene stimulates in vivo functional neovascularization
To investigate whether systemically administered Tazarotene enhanced in vivo neovascularization, we tested its efficacy in Matrigel implants implanted in mice. Intra-peritoneal administration of Tazarotene was well tolerated ( Supplementary Fig. 5 ) and resulted in enhanced expression of hepatic RARRES1 (a retinoid pathway target 22 ) indicating that Tazarotene was systemically bioactive ( Supplementary Fig.   6 ). The invasion and the growth of microvessels into the Matrigel implant was quantified by CD31 and -smooth muscle (SM) actin staining of endothelium and mural cells, and was significantly higher following systemic Tazarotene. Moreover, the neovessels formed appeared more mature and covered by mural cells (α-SM actin positive cells) ( Fig. 5b) . We quantified neovessel perfusion by perfusing mice with Microfil, and imaged dissected plugs using microCT. Microvessels penetrating the Matrigel implant are more abundant in the Tazarotene treated group (7-folds versus control) and invading neovessels penetrate deeper into the gel (Fig. 5c ). To visualize the structure and perfusion of microvasculature at a cellular level, we perfused mice with biotinylated-isolectinB4. Thick section A c c e p t e d m a n u s c r i p t preparations of Matrigel revealed that Tazarotene increased the formation of microvessels with an enhanced capacity to receive flow whereas fewer microvessels could be identified in control mice (Fig.   5d ).
Tazarotene enhances wound vascularization and healing
Angiogenesis is a critical part of the normal healing process. New blood vessels deliver oxygen, nutrients, and essential growth factors to injured tissues 29 . To assess its effect on wound angiogenesis, first we used an ear punch wound model. The ear punch model is an established model of wound healing model and has been widely used to study wound healing, tissue regeneration, innervation and neovascularization 30, 31, 32, 33 . In particular, quantitative analysis of new vessel formation and wound morphometry is feasible in this model. Tazarotene was injected intra-peritoneallly for six days following injury. The group treated with Tazarotene showed a remarkable acceleration of wound closure measured after 12 days (Fig. 6a ). Blood flow and tissue perfusion was measured by contrast speckle laser imaging at 6 and 12 days following injury and was significantly enhanced in the regenerating area of the Tazarotene-treated group (Fig. 6b ). Histologically, a major difference in ear hole size with neogenesis of hair follicles ( Fig. 6c, Supplementary Fig. 7 ) was apparent at the wound margins by day 14 after
Tazarotene. The re-differentiation events such as hair follicle growth are considered later morphogenetic events in the regenerative healing process 34 . Collagen is a major extracellular matrix component of skin and essential for the mechanical properties of the wounded region. We assessed the collagen fiber networks using staining with picrosirius red (a dye for collagen fiber maturity 35 ). The new and mature collagen levels were increased in the regenerated area in the Tazarotene-treated group compared to the control group. Collagen fiber morphology and organization was close to that observed in the normal skin in the Tazarotene treated group (Fig. 6c ). Proliferating cells were more abundant in regenerating area of the Tazarotene-treated group. The majority of the proliferating cells were epithelial (K14 positive) cells).
Fewer proliferating cells were detected in the vessels or myofibroblasts (α-smooth muscle cell positive A c c e p t e d m a n u s c r i p t cells) ( Fig. 6d ). Blood vessel densities in the regenerated ear margin of Tazarotene-treated mice were 4.5-folds greater than that seen in Vehicle-treated mice (Fig. 6e ). Confocal microscopy of ear whole mount revealed an augmented neovessel growth in the regenerated tissue of the Tazarotene-treated group at 14 days after injury. Notable, a significant increase of sprouting vessels towards the wound edge is detected as early as 4 days after injury (Fig 6f,g) . The ear punch model provides cartilage as the wound bed. To further explore the therapeutic potential of Tazarotene in a model that does not involve cartilage, we have used a dermal excisional wound model. In agreement with our previous findings in the ear punch wound model, we found that animals treated with Tazarotene showed an acceleration of wound healing (Fig 7a) . Histological analysis revealed that Tazarotene increased wound epithelialization (Fig 7b) and enhanced new microvessel growth (Fig 7c) in the wound bed compared to the control group. Together, these data show that Tazarotene induces wound tissue repair associated with increased neovascularization of the wound bed.
Discussion
In the present study, we used high content imaging techniques and a combination of two phenotypic angiogenesis assays to screen a small molecule library with well-defined targets. This resulted in the identification of Tazarotene, a third generation retinoid agonist, as a pro-angiogenic small molecule. We showed that Tazarotene promotes blood vessel growth and functional neovascularization in several in vitro and in vivo systems that model angiogenesis. This is a novel supporting evidence that Retinoic acid can have angiogenesis-promoting activity 39 .
At a cellular level, we show that
We showed that blockade of retinoic acid degradation, which leads to increase the intracellular level of retinoic acid, induces the sprouting angiogenic behavior of endothelial cells similar to Tazarotene. The intracellular level of retinoic acid is maintained by the balance between its synthesis and degradation into inactive products, and is regulated by an enzymatic network in which retinol dehydrogenases (RDH) and retinaldehyde dehydrogenases (RALDHs) synthesize, while cytochrome the P450 CYP26 degrades retinoic acid 40 . This generates gradients of retinoic acid signaling activity that are distributed in a dynamic spatiotemporal manner to create important control mechanisms during organ development 41, 42 . We speculate that such gradients may similarly program the sprouting and remodeling process during new vessel formation. The regulation of intracellular retinoic acid availability could thus be an important factor in controlling the different cellular events of angiogenesis. Tazarotene when cultured in isolation. We speculate that this difference may be due to the experimental conditions, the most important being that we used a co-culture with endothelial cells.
The pro-angiogenic properties of Tazarotene, identified in our cell-based studies, were confirmed in relevant in vivo models -Matrigel implant and wound healing. In both models, angiogenesis is preceded by fibroblast growth and invasion. In the Matrigel plug model, we show that Tazarotene enhanced the formation of an anatomically mature neovessel network that was physiologically functional and able to receive blood flow. Moreover, we found that Tazarotene induced sprouting angiogenesis and capillary growth from an early stage of the healing process. Capillary growth into the wound allows delivery of nutrients, cells, and cytokines that mediate the healing response, and is necessary for metabolite removal. Insufficient angiogenesis thus impairs wound healing 46 In summary, we demonstrate that Tazarotene promotes neovascularization and tissue repair through its action on retinoic acid signaling. At least in part, this is driven by a Tazarotene-induced pro-angiogenic paracrine signaling from fibroblasts. Tazarotene is a small molecule with a defined mechanism of action, and is approved for topical use by the FDA 15 . Oral Tazarotene does not appear to be associated with adverse events that are typical of oral retinoids, including hypertriglyceridemia and hypercholesterolemia 48 . Thus, re-purposing of Tazarotene could be explored for treatment of pathological conditions where circulatory insufficiency is a significant factor for instance in delayed wound healing 49 .
Materials and Methods
Chemical compounds
The experiments. The in vitro tube formation assay was performed as previously described for a 96-well microplate format 13 . In our study, we also adapted the assay for 384-well microplate format. Images were acquired using a high-content imaging system (Operetta, Perkin Elmer). The raw (.tiff) images were then segmented and analyzed to extract the morphological features of vascular-like network using fully-automated Metamorph image analysis software (Molecular Devices). The Z' factor was used to measure the robustness of the cell-based assay. It is defined by the following equation:
Assays with Z>0.3 are considered highly suitable for conducting a high-throughput screening of assays with complex cellular systems such as capillary-like network formation 50 . We found that the most robust morphological parameter is total tube length (Z' factor=0. 33) . For the actual screen, several other parameters depicting the network morphometric were also measured including branching points, average tube thickness, total tube area, total node area, tube length per set and segment number. Endothelial tubes were fixed with paraformaldehyde 4% overnight at 4°C. After washing with PBS, cells were permeabilised with 0.1% Triton X-100 in PBS for 10 min. Cells were stained with alexa fluor-568 phalliodin (Invitrogen), 1:200 and HCS CellMask™ Green (Invitrogen), 1:5000 for 45 min at room temperature. Wells were washed three times with 0.05% TWEEN-20 in PBS. Next, the plates were imaged with a 2x objective using a high-content microcopy system (Operetta, Perkin Elmer). A single field which covers the whole well was acquired at two wavelengths to image cell body (CellMask green) staining and actin phalloidin staining at exposure times of 50 and 400 milliseconds, respectively.
The actin-phalloidin images (16-bit depth) were cropped using imageJ (NIH) to extract the region-ofinterest from the row images and to remove the out-of-focus objects in the border area of the well. Each resulting well image had a dimension of 400x400 pixels, which covers 45% of the total area of the well.
Next, the processed images were segmented and analyzed to extract the morphological features of the vascular-like network using fully-automated Metamorph image analysis software (Molecular Devices).
A pixel intensity threshold was set to distinguish actin-labeled endothelial tubes from local background along with a minimum and maximum tube width and applied for analysis of all images. The total tube length and branching points reading values were normalized using the B-score method in the WebCellHTS2 package 51 . The hit selection threshold was set at +2.6 for enhancers and at -4.0 for inhibitors. R 2 correlation between replicates was =0.7. The Z' factor was used to assess the quality control of the screen plates, and was >0.3 in all plates (Supplementary Fig. 2a ). The screen data and plate QC assessment were visualized and analyzed using Excel (Microsoft), Spotfire (TIBCO, Perkin Elmer) and Prism (GraphPad) software.
Co-culture angiogenesis assay
Adult human dermal fibroblasts (HDF, Lonza) were seeded at density 15,000 cells per well. Next day, HUVEC were plated at density 4,000 cells per well on the confluent fibroblast monolayer in 96-well plate as described previously 52 . The interaction of these two cell types gives rise to three-dimensional tubules over a period of 5-7 days. The drug is added one hour after plating of HUVEC to avoid potential secondary effect of the drug on cell adhesion. The co-cultures were fed with a full-growth factor supplemented medium consisting of a 1:1 mixture of medium-106 (Invitrogen): EGM-2 medium.
Endothelial formed tubes were assessed by immunofluorescence using a mouse anti-human CD31 monoclonal antibody (ref. BBA7, R&D systems) at 1:100 dilution and goat alexa 568-conjugated antimouse IgG secondary antibody (Invitrogen) at 1:400 dilution. Nuclei were visualized by DAPI staining.
The endothelial tubes were imaged automatically at 10x magnification using the high-content imaging system (Operetta). Typically, nine identically positioned fields were acquired from each well in each experiment. Quantification of the angiogenic parameters of formed endothelial network was performed automatically using Metamorph software.
Heat map clustering and analysis for phenotypic profiling of compounds
Prior to hierarchical clustering, data were scaled by performing Z score normalization for each angiogenic parameter. Z score-transformed values were then clustered using an unsupervised A c c e p t e d m a n u s c r i p t agglomerative clustering method with an average linkage and a Euclidian distance measurement 53 .
Hierarchical clustering of the compound phenotype profiles was carried out using TIBCO Spotfire software and data were visualized using the dendrogram for compounds with heat map for angiogenic parameter values. hours before fixation. Next, the cultured cells were fixed with 4% paraformaldehyde for 10 min and treated with 0.1% Triton X-100 for 15 min at room temperature. After washing with PBS, the samples were stained with Click-iT® reaction cocktail working solution at room temperature for 30 min. The cells were stained with DAPI at room temperature for 20 min. In co-culture experiments, endothelial cells were stained with mouse anti-human CD31 antibody (R&D systems) and subsequent incubation with alexa568-conjugated goat anti-mouse IgG secondary antibody (Invitrogen). The plates were imaged and quantified using high-content fluorescent microscopy (Operetta). The total cell number and percentage of EdU-positive cells was calculated from 9 fields per well using a 10x objective (Harmony software, Perkin Elmer). The image analysis software (Harmony) has the required algorithms to be able to distinguish the nuclei in stained endothelial tubes from the ones of fibroblasts. 
Cell proliferation assay
Time-lapse live cell imaging and cell motility assessment
ELISA
We used commercially available enzyme-linked immunosorbent assay (ELISA) kits (DuoSet, R&D systems) to measure thuman Placental Growth factor (PGF) and Pentatraxin 3 (PTX3) levels in cell culture supernatants.
In vivo Matrigel implant angiogenesis assay
Experiments involving mice were covered by project and personal licenses issued by the UK Home To visualize microvessel perfusion, terminally anesthetized mice were injected intracardially with 3mg/kg of biotinylated GS-IsolectinB4 (invitrogen). After 5 min, mice were euthanized and perfused with 4% neutral buffered paraformaldyhede under physiological pressure. Implants were dissected and stored in PFA 4% overnight. Following an incubation in 30% (w/v) sucrose solution, the plugs were embedded in OCT compound and were snap frozen. Implants were cut into thick sections (200µm) and labeled for injected lectin by incubating with alexa647-conjugated streptavidin. Co-staining is applied to visualize the total vessels by incubating with anti-CD31 antibody as described above. Fluorescence images of stained slices were taken with a confocal laser-scanning microscope (Zeiss 510 Metahead).
Around 50 z-stacks of raw images (xy) were required for 3D reconstruction.
MicroCT angiogram
Mice were euthanized, and the thoracic cavity was opened. The right atrium was cut, and the heart (left 
Ear punch wound healing model
Eight-week old female CD1 mice (Harlan Laboratories) were used for an ear wounding procedure as described previously 55 Samples were incubated for with alexa488-conjugated goat anti-rat IgG secondary antibody (Invitrogen) and Cy3-conjugated anti--SM actin antibody (Sigma). Nuclei were counterstained with DAPI (Invitrogen). CD31-positive blood vessel area was quantified in the marginal area of wounds using Image J software. Fluorescent images from flat-mounted ear skins were visualized using a Leica SP8 SMD X Confocal Microscope. Around 60 z-stacks of raw images (xy) were typically acquired for 3D reconstruction.
Laser speckle contrast imaging of blood flow
Blood flow in the ear wounds was monitored using a Speckle Contrast Imager -FLPI-2 (Moor Instruments, UK) as described previously 56 . The FLPI measurements were made in a warm (24 °C) and quiet environment. The CCD camera was positioned 30 cm above the ear internal surface. The contrast images were processed to produce a color-coded live flux image (red denoted high perfusion, blue signified low perfusion) using the moorFLPI-2 measurement module (Moor Instruments). Measurements were made postoperatively in the periphery area of wounds at 6 and 12 days using the moorFLPI-2 review module (Moor Instruments).
Excisional dorsal wound healing model
Eleven-week old female CD1 mice (Harlan Laboratories) were used for cutaneous wounding procedure as described previously 57 . All procedures were carried out according to UK Home Office regulations and under appropriate license. Mice were anesthetized, and their dorsal skin was shaved and wiped with 70% ethanol. Full-thickness excisional wounds were made by picking up a fold of skin and using a sterile, A c c e p t e d m a n u s c r i p t
